Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 15/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 14/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17651814 | 1.00 | HSD17B1 (0.38) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL249200 | 0.88 | HSD17B1 (0.47) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL19278973 | 0.84 | LCK (0.30) | — | |
| SCHEMBL17651804 | 0.84 | TSHR (0.34) | PIK3CG | |
| SCHEMBL17651772 | 0.84 | TSHR (0.34) | PIK3CG | |
| SCHEMBL4411632 | 0.83 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4411533 | 0.83 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4412721 | 0.83 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL19837814 | 0.83 | PIK3CG (0.30) | PIK3CG | |
| SCHEMBL17651802 | 0.83 | PIK3CG (0.30) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3201201-B1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2022-01-26 | — | — | EP | disclosed |
| US-10738059-B2 | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2020-08-11 | — | — | US | disclosed |
| US-10456375-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2019-10-29 | — | — | US | disclosed |
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2018-02-08 | — | — | US | disclosed |
| US-20170247384-A1 | CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2017-08-31 | — | — | US | disclosed |
| EP-3210626-A1 | CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY | biolitec Unternehmensbeteiligungs II AG (AT) | 2017-08-30 | — | — | EP | disclosed |
| EP-3201201-A1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | biolitec unternehmensbeteiligungs II AG (AT) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016051361-A1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | DHPS, DDT, PPOX | HSD17B1 4141/4885HSD17B2 4046/4885CYP3A4 2334/4885 |
| US-10456375-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | DHPS, DDT, PPOX | HSD17B1 4141/4885HSD17B2 4046/4885CYP3A4 2334/4885 |
| US-10738059-B2 | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy | FPGS, PPOX, UROD | HSD17B1 1760/4885HSD17B2 2251/4885CYP3A4 1690/4885 |
| US-20170247384-A1 | CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY | FPGS, PPOX, UROD | HSD17B1 1760/4885HSD17B2 2251/4885CYP3A4 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.